Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.57), $0.25 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $4.78 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.